Replimune shares plummet as skin cancer therapy fails mid-stage study
Replimune Group's experimental combination therapy for skin cancer, involving its lead therapy RP1 and Regeneron's Libtayo, failed to significantly re
Stay updated with breaking news from Bmo Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replimune Group's experimental combination therapy for skin cancer, involving its lead therapy RP1 and Regeneron's Libtayo, failed to significantly re
We recently passed an anniversary, of sorts – one year to the day since the stock market hit bottom. On October 12 of last year, the S&P 500 reached its trough; since then, the market trend has been upward despite some volatility and a recent pullback. Brian Belski, chief investment strategist from BMO Capital, believes that we’re into a secular bull market now. Looking at a series of factors – general economic growth, the slowing pace of inflation, the stage of the Fed’s monetary policy, Belski
Analysts mostly hailed ServiceNow Inc.'s Q4 results by raising their price targets. Piper Sandler analyst Rob Owens upgraded ServiceNow to Overweight from Neutral with ...
BMO Capital analyst Daniel Salmon lowered the price target on Amazon.com Inc. to $3,600 from $4,100 but reiterated an Outperform rating on the ...
Shares closed down 24 per cent on Thursday, wiping off nearly $2.5bn in market valuation